Anxiety and trauma disorders: GAD, PTSD, OCD; fear conditioning models

Intuition Beginner

Anxiety is a normal response to threat, but anxiety disorders involve excessive fear that interferes with daily life. Generalized anxiety disorder (GAD) means chronic, excessive worry about many things — money, health, family — that lasts months and resists control. Panic disorder brings sudden, intense attacks of fear with physical symptoms: a racing heart, shortness of breath, chest pain, dizziness, a choking feeling. These attacks peak within minutes and feel like dying or losing one's mind.

Phobias are the most common anxiety disorders. A specific phobia is an intense fear of a particular object or situation — spiders, heights, flying, injections, blood. Social anxiety disorder is a marked fear of social or performance situations, driven by dread of embarrassment or negative evaluation. Agoraphobia is fear of places where escape might be hard or help unavailable — crowds, public transport, open spaces. In each case the fear is out of proportion to real danger and leads to avoidance that narrows a person's life.

OCD, PTSD, and the fear circuit Beginner

Obsessive-compulsive disorder (OCD) involves unwanted intrusive thoughts called obsessions — images, impulses, or doubts that feel alien and distressing, such as fears of contamination or of harming a loved one. These drive compulsions: repetitive behaviors like washing, checking, or counting, or mental acts like silent praying, performed to reduce the anxiety the obsessions create. The relief is temporary, so the cycle repeats, sometimes for hours each day, and the disorder can become disabling.

Post-traumatic stress disorder (PTSD) develops after a terrifying experience — combat, assault, an accident, a disaster. Sufferers re-live the event through flashbacks and nightmares, avoid reminders, and stay stuck in a state of heightened alert. A slammed door can trigger a combat memory; a crowded street can feel dangerous. Sleep, concentration, and relationships suffer.

Joseph LeDoux showed that the amygdala, an almond-shaped cluster of neurons deep in the brain, processes fear before the conscious cortex even registers the threat. Sensory input reaches the amygdala by a fast, rough pathway and by a slower, detailed one. This is why fear feels automatic and hard to control: the alarm fires before reflection can intervene. The same circuitry, over-reactive or slow to calm, underlies the disorders above.

Visual Beginner

The diagram maps the disorder categories against the shared neural machinery — the dual-route amygdala circuit, hippocampal context tagging, prefrontal extinction, and the HPA stress axis — that the rest of the unit develops.

Check your understanding Beginner

Formal definition Intermediate

The DSM-5-TR splits what was once a single "anxiety disorders" chapter into three clusters: anxiety disorders, obsessive-compulsive and related disorders, and trauma- and stressor-related disorders. This separation reflects growing evidence that OCD and PTSD differ from the anxiety disorders in genetics, neural circuitry, and treatment response, though all are bound together by dysregulated fear ^{[DSM-5-TR 2022]}.

Generalized anxiety disorder (GAD). Excessive anxiety and worry, occurring more days than not for at least six months, about a number of events or activities. The worry is difficult to control and is accompanied by three or more of six symptoms: restlessness or feeling on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. The symptoms cause clinically significant impairment and are not attributable to a substance or medical condition.

Panic disorder. Recurrent, unexpected panic attacks — abrupt surges of intense fear or discomfort that peak within minutes and bring four or more of thirteen symptoms (palpitations, sweating, trembling, shortness of breath, choking, chest pain, nausea, dizziness, chills or heat sensations, paresthesias, derealization or depersonalization, fear of losing control, fear of dying). At least one attack is followed by one month or more of either persistent concern about further attacks, worry about their consequences, or a significant maladaptive change in behavior.

Specific phobia. Marked fear or anxiety about a specific object or situation; the fear response is immediate and almost inevitable; the stimulus is avoided or endured with intense fear; the fear is out of proportion to the actual danger; the duration is at least six months; the condition causes impairment. Common subtypes are animal, natural-environment, blood-injection-injury, situational, and other.

Social anxiety disorder. Marked fear or anxiety about one or more social or performance situations in which the person may be scrutinized and negatively evaluated. The individual fears showing anxiety or acting in a humiliating way, avoids the situations or endures them with fear, the fear is out of proportion, lasts at least six months, and causes impairment.

Agoraphobia. Marked fear or anxiety about two or more of five situations: using public transport, being in open spaces, being in enclosed spaces, standing in line or being in a crowd, and being outside the home alone. The situations are feared because escape might be difficult or help unavailable, are avoided or endured with fear, the fear is out of proportion, lasts six months or more, and causes impairment.

Obsessive-compulsive disorder. The presence of obsessions, compulsions, or both. Obsessions are recurrent, persistent, intrusive thoughts, urges, or images that the person attempts to ignore, suppress, or neutralize. Compulsions are repetitive behaviors (hand-washing, checking, ordering) or mental acts (praying, counting, repeating words) that the person feels driven to perform, either in response to an obsession or according to rigid rules, aimed at reducing anxiety or preventing a dreaded outcome, but not realistically connected to that outcome or markedly excessive. The symptoms are time-consuming (more than one hour per day) or cause impairment. DSM-5 specifiers record degree of insight and whether the disorder is tic-related.

Post-traumatic stress disorder (PTSD). Criterion A requires exposure to actual or threatened death, serious injury, or sexual violence, in one or more ways: directly experiencing it; witnessing it; learning it happened to a close family member or friend (the death must be violent or accidental); or experiencing repeated or extreme exposure to aversive details (as in first responders). Criterion B (intrusion, one or more) comprises intrusive memories, distressing dreams, dissociative reactions including flashbacks, intense psychological distress at cues, and marked physiological reactivity to cues. Criterion C (avoidance, one or more) is avoidance of memories, thoughts, or feelings, and avoidance of external reminders. Criterion D (negative alterations in cognition and mood, two or more) covers inability to recall key aspects of the trauma, distorted negative beliefs about oneself or the world, blame, persistent negative emotional state, diminished interest, detachment, and inability to experience positive emotions. Criterion E (alterations in arousal and reactivity, two or more) covers irritability and aggression, reckless or self-destructive behavior, hypervigilance, exaggerated startle, concentration problems, and sleep disturbance. Criterion F requires duration of one month or more; Criterion G requires clinically significant distress or impairment; Criterion H excludes substances and medical conditions. Specifiers record dissociative symptoms (depersonalization, derealization) and delayed expression.

Acute stress disorder. Shares the trauma-exposure criterion and a similar symptom profile, but lasts from three days to one month after trauma exposure. Persistence beyond one month prompts a PTSD assessment.

Prevalence and course. Anxiety disorders are the most common class of mental disorder. Lifetime estimates are approximately 7% for GAD, 3-5% for panic disorder, 9-12% for specific phobia, 7-12% for social anxiety disorder, and 1-3% for agoraphobia. OCD has a lifetime prevalence of about 1.2-2.4%. PTSD has a lifetime prevalence of roughly 6-9% in US adults, though most trauma-exposed people do not develop it — a key clue to the role of individual vulnerability factors. Women are diagnosed with anxiety disorders at roughly twice the rate of men. Onset is typically in childhood or early adulthood, and the course is often chronic and relapsing without treatment.

Key mechanism: fear conditioning and the amygdala circuit Intermediate

Fear conditioning is the laboratory model that anchors nearly all mechanistic accounts of the disorders above. In classical fear conditioning, a neutral conditioned stimulus (CS) — a tone, a light, a context — is paired with an aversive unconditioned stimulus (US) such as a shock. After pairing, the CS alone elicits a conditioned fear response: freezing, increased startle, autonomic arousal. Learned fear can be acquired in a single trial and lasts for years, which is why a single trauma can leave a durable trace ^{[LeDoux 1996]}.

LeDoux's central anatomical insight is that sensory information reaches the amygdala by two routes. The "low road" runs from the thalamus directly to the amygdala: it is fast and crude, carrying only a rough sketch of the stimulus, and it operates outside conscious awareness. The "high road" runs from the thalamus to the sensory cortex and then to the amygdala: it is slower and carries fine-grained, consciously accessible detail. The low road lets the organism mount a defensive response before it knows precisely what the threat is; the high road allows later appraisal and correction. This dual architecture explains why a snake-shaped stick can trigger a full startle before one recognizes it is harmless — and why fear, once triggered, is so hard to talk down.

Contextual fear and the hippocampus. The amygdala encodes that something is dangerous; the hippocampus encodes where and when it was dangerous. Rats shocked in a particular chamber freeze when returned to that chamber, and humans with hippocampal damage can show intact fear conditioning but impaired contextual modulation. In PTSD, this contextual tagging is thought to fail: a trauma memory, triggered by a cue, is experienced as happening now rather than then, and the amygdala's alarm generalizes across safe contexts ^{[Gleitman 2011]}.

Extinction learning and the prefrontal cortex. Repeated presentation of the CS without the US weakens the conditioned fear response — a process called extinction. The crucial finding, established by Bouton and others, is that extinction is not erasure: the original association remains intact beneath a new, inhibitory association. The evidence is that extinguished fear returns under three conditions. Renewal: fear returns when the CS is encountered in a context different from the one where extinction took place. Spontaneous recovery: fear returns with the passage of time. Reinstatement: an unsignaled US brings the fear back. The infralimbic prefrontal cortex in rodents (ventromedial PFC in humans, studied by Phelps and colleagues) is required to retrieve and maintain the extinction memory — it puts the brakes on the amygdala. This single fact reframes exposure therapy as the cultivation of new inhibitory learning, and it predicts why relapse is common and why extinction-based treatments must be repeated across contexts.

The HPA axis and cortisol. Threat also engages the hypothalamic-pituitary-adrenal axis. The hypothalamus releases corticotropin-releasing hormone (CRH), which prompts the pituitary to release adrenocorticotropic hormone (ACTH), which prompts the adrenal cortex to release cortisol. Cortisol mobilizes energy for immediate action. Chronically elevated cortisol, however, damages the hippocampus (which is rich in glucocorticoid receptors and normally provides negative feedback) and sensitizes amygdala reactivity, producing a feed-forward loop that is implicated in the persistence of anxiety and in the smaller hippocampal volumes seen in PTSD.

Bridge. The conditioning, contextual, extinction, and endocrine mechanisms are not rival theories but four layers of one defensive system. The master tier unpacks each layer — amygdala subnuclei and synaptic plasticity, the neural models of PTSD and OCD, the pharmacological targets, and the reconsolidation- and MDMA-based treatments now in late-phase trials.

Exercises Intermediate

Advanced models and treatments Master

Amygdala subnuclei and synaptic plasticity

The amygdala is not a monolith. Fear conditioning research, much of it in rodents, parcels it into functionally distinct subnuclei. The lateral amygdala (LA) is the input gateway and the chief site of plasticity: it is where the CS and US representations converge, and where long-term potentiation (LTP) at the synapses carrying the CS signal stores the CS-US association. Davis, LeDoux, and colleagues showed that blocking NMDA-receptor-dependent LTP in LA during conditioning abolishes fear learning, while stimulating those same inputs can induce it. The central amygdala (CE) is the output hub: its neurons project to brainstem and hypothalamic targets that generate the measurable fear responses — freezing, startle potentiation, autonomic surge, HPA activation. The basal (basolateral) amygdala contributes contextual and motivational modulation, interfacing with the hippocampus and prefrontal cortex to gate when and how strongly LA-CE outputs are expressed.

This input-learning-output division matters clinically. A drug or therapy that dampens CE output reduces fear expression without touching the stored memory, so the fear can return — precisely the extinction-and-relapse pattern described below. A treatment that disrupts reconsolidation at LA synapses, by contrast, aims at the memory trace itself.

Fear extinction: inhibitory learning, not erasure

Extinction was once read as the unlearning or decay of fear. Bouton's reframing overturned that. Extinction installs a new, context-dependent inhibitory memory that competes with the original. The original association survives, which is why extinguished fear recovers under renewal (context shift), spontaneous recovery (time), and reinstatement (unsignaled US). The infralimbic prefrontal cortex in rodents — homologous to human ventromedial prefrontal cortex — stores and retrieves the extinction memory, exerting top-down inhibition over the amygdala. Phelps and colleagues extended this work to humans using neuroimaging, showing that vmPFC activity during extinction recall predicts the strength of fear suppression.

This reframing reshaped exposure therapy. Because extinction is fragile and context-bound, exposure must be repeated, varied across contexts, and consolidated over time, or relapse is the expected outcome. The implication is that exposure therapy succeeds not by erasing fear but by building a competing safety memory robust enough to win the retrieval race.

PTSD models

Three converging models explain why a trauma becomes persistent.

The fear conditioning model holds that PTSD reflects over-consolidation of the trauma memory — the intense stress at encoding drives strong amygdala-driven consolidation — combined with impaired extinction. People with PTSD show smaller hippocampi, hyperreactive amygdalae, and hypoactive vmPFC on imaging, the exact profile that would impair contextual tagging and extinction retrieval. A car backfire, processed through a generalized amygdala with poor contextual gating and weak prefrontal brakes, is read as the attack is happening again rather than a car backfired.

Brewin's dual representation theory distinguishes two memory systems. Verbally accessible memories (VAMs) are consciously retrievable, narratable, and integrated with autobiographical context. Situationally accessible memories (SAMs) are sensory-rich, fragmentary, and re-experienced involuntarily during flashbacks. In PTSD the SAMs are too intense to be processed and integrated into VAMs, so they persist as raw, here-and-now sensory intrusions. Therapy works by transforming SAMs into VAMs — which is exactly what prolonged exposure and narrative reconstruction attempt.

Foa's emotional processing theory proposes that PTSD reflects a pathological fear structure — a mental representation in which the world and the self are coded as comprehensively dangerous and worthless. Exposure therapy modifies this structure by activating it (re-engaging the fear network) and disconfirming it (providing corrective information that the world is safe and the self can cope). Without activation, the structure cannot be edited; without disconfirmation, the structure cannot change. This dual requirement — activation plus disconfirmation — is the mechanism Foa assigns to imaginal and in vivo exposure.

OCD: cortico-striato-thalamo-cortical circuits

OCD's neurobiology points away from the amygdala and toward frontal-basal ganglia loops. The cortico-striato-thalamo-cortical (CSTC) circuit links the orbitofrontal cortex, anterior cingulate, caudate nucleus, globus pallidus, and thalamus in a recurrent loop. Structural and functional imaging consistently show caudate hyperactivity and orbitofrontal overactivation in OCD, which normalize after successful treatment (whether SSRI or behavior therapy). Baxter's early PET studies established this pattern, and it has held up across decades. Neurochemically, serotonin is implicated by the preferential efficacy of serotonergic agents, but glutamate has gained attention, with glutamate-modulating agents (such as riluzole and ketamine) showing signals in refractory cases.

The pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) hypothesis posits that, in a subset of children, streptococcal antibodies cross-react with basal ganglia tissue and trigger abrupt OCD-like symptom onset. The hypothesis remains controversial: the epidemiology is inconsistent, the mechanism uncertain, and prophylactic antibiotic or immunomodulatory treatment is not standard. It is best regarded as a possible contributor in a small, hard-to-define subgroup rather than a general explanation for OCD.

Pharmacological treatment targets

Drug treatment for the anxiety disorders, OCD, and PTSD converges on a small set of mechanisms. SSRIs are first-line for GAD, panic disorder, social anxiety, OCD, and PTSD; they are broad-spectrum but slow, taking weeks to act, and they are only partially effective. SNRIs (venlafaxine, duloxetine) are comparable alternatives. Buspirone, a 5-HT1A partial agonist, is a non-sedating, non-addictive option for GAD, though slower in onset and less effective than benzodiazepines. Benzodiazepines — alprazolam, clonazepam, diazepam — are positive allosteric modulators of the GABA-A receptor that act within hours. They are effective anxiolytics but carry substantial costs: tolerance, dependence, a withdrawal syndrome, cognitive impairment, and additive sedation with alcohol. For these reasons they are now recommended only for short-term or as-needed use, not as maintenance treatment. The chronic-use gap left by benzodiazepines is exactly what SSRIs and CBT fill.

Exposure therapy and CBT

The behavioral descendants of fear-conditioning research dominate psychotherapy for these disorders. Systematic desensitization (Wolpe) pairs graded exposure to feared stimuli with relaxation, building an inhibitory relaxation response. Flooding skips the grading and exposes the patient to the most feared stimulus at maximum intensity, relying on the fact that autonomic arousal cannot be sustained indefinitely. Both rest on the same extinction logic.

Exposure can be imaginal (mentally revisiting the trauma, central to PTSD treatment) or in vivo (entering the avoided situation, central to phobia and agoraphobia treatment). Virtual reality exposure extends in vivo work to stimuli that are costly or impractical to arrange, such as combat zones or airplane cabins. Eye movement desensitization and reprocessing (EMDR) asks patients to track lateral hand movements while imagining a trauma; although it is clinically popular and guideline-endorsed, dismantling studies suggest the eye movements add little beyond ordinary imaginal exposure, and that the exposure component is the active ingredient. The honest reading is that EMDR is a serviceable delivery vehicle for exposure therapy rather than a mechanistically novel treatment.

PTSD, reconsolidation, and MDMA

Two lines of research aim beyond extinction toward the memory trace itself.

Memory reconsolidation. When a consolidated memory is reactivated it briefly re-enters a labile state before being re-stored — the reconsolidation window. Brunet and Pitman and colleagues administer the beta-blocker propranolol during trauma-memory reactivation, exploiting the reconsolidation window to weaken the emotional tone of the reactivated memory while leaving its factual content intact. The effect is not full erasure, and replications have been mixed, but the approach opened a programmatically new strategy: editing a memory at the moment it is most plastic.

MDMA-assisted psychotherapy. In the MAPS Phase 3 trials led by Mithoefer and colleagues, MDMA is administered alongside structured psychotherapy sessions. MDMA dampens amygdala reactivity, raises serotonin, and releases oxytocin, which is thought to enhance therapeutic alliance and empathy, reduce defensiveness, and allow patients to revisit traumatic memories without being overwhelmed. Phase 3 results showed large effects on PTSD severity relative to placebo plus therapy. MDMA is a tool for enabling exposure and emotional processing under conditions of felt safety, not a standalone pharmacological cure. The same logic — pharmacologically enabling a psychotherapy that the disorder's psychopathology would otherwise block — is the active rationale.

Etiological models for GAD

Two models frame why worry itself becomes the pathology in GAD. Dugas's intolerance of uncertainty model holds that individuals with GAD react to uncertainty as intolerable and respond with worry as a cognitive attempt to reduce it; because worry cannot eliminate uncertainty, it self-perpetuates. Barlow's triple vulnerability model specifies three interacting vulnerabilities: a generalized biological vulnerability (heritable neuroticism), a generalized psychological vulnerability (early experiences teaching that events are uncontrollable), and a specific psychological vulnerability (learning to focus anxiety on particular domains). The disorders emerge when stress activates all three. This integrative framing accounts for why anxiety disorders run in families yet are shaped by learning, and why they cluster and comorbidify so readily.

Synthesis. The fear-conditioning, contextual, extinction, CSTC, reconsolidation, and vulnerability accounts are layered rather than competing. Shared amygdala-driven alarm, modulated by hippocampal context and prefrontal inhibition, disrupted in different ways across the anxiety disorders, OCD, and PTSD, is the unifying substrate; the specific disorders mark which layer breaks down most. Treatment succeeds when it engages the right layer — exposure for the extinction layer, SSRIs for the neurochemical layer, CSTC-directed and glutamate strategies for OCD, and reconsolidation- and MDMA-enabled work for the memory-trace layer of PTSD.

Connections to other disciplines Master

Anxiety and trauma disorders sit at the intersection of affective neuroscience, learning theory, endocrinology, and pharmacology. The amygdala-cortex-PFC circuitry connects this unit directly to the neuroscience chapters (29.02), particularly the units on brain regions and neurotransmitter systems. Fear conditioning is a direct application of classical conditioning (29.04.02), and the extinction-as-inhibitory-learning analysis builds toward the memory-systems unit (29.04.03) and the forgetting-and-false-memory unit (29.04.04), where reconsolidation and memory malleability recur.

The HPA-axis and cortisol material links to the motivation and emotion unit (29.11.01) and to the developmental and stress-diathesis themes of the disorders chapter. The pharmacology — SSRIs, benzodiazepines, GABA-A modulation, glutamate agents — connects to the therapy and treatment unit (29.10.01), where the common-factors versus specific-ingredients debate and the evidence base for CBT and exposure are taken up in full. The vulnerability and diathesis-stress models reach back to the diagnostic-validity debates of the disorders-introduction unit (29.09.01) and forward to the psychotic-disorders unit (29.09.04), where the same stress-diathesis logic returns for schizophrenia.

The cultural material is thinner here than for mood disorders, but it matters: the expression of trauma and the legitimacy granted to dissociative and somatic presentations vary across cultures, connecting to cross-cultural and indigenous psychology (29.12). The philosophical question of whether a trauma memory is a stored representation or a reconstructed narrative reappears, sharpened by the reconsolidation and MDMA findings, which press on the metaphysics of memory.

Historical and philosophical context Master

The idea that pathological fear is disordered ordinary fear is ancient, but its mechanistic grounding is recent. Pavlov and Watson established fear conditioning in the early twentieth century, and Watson's "Little Albert" experiment (1920) — ethically indefensible by modern standards — demonstrated that a phobia could be acquired through conditioning. For most of the century, however, anxiety disorders were discussed in psychoanalytic terms as symptoms of unconscious conflict. The behavioral turn, led by Wolpe's reciprocal inhibition therapy in the 1950s, reframed phobias and anxiety as learned responses that could be unlearned, and laid the foundation for today's exposure therapies ^{[Gleitman 2011]}.

LeDoux's amygdala work from the late 1980s onward gave the behavioral account a neural substrate. By tracing the anatomical pathways through which sensory input reaches the amygdala, he showed that the brain possesses a rapid, subcortical fear system operating outside the cortex. The Emotional Brain (1996) popularized the low-road/high-road distinction and placed the amygdala at the center of affective neuroscience ^{[LeDoux 1996]}. This was both a scientific advance and a conceptual reframing: fear became a circuit phenomenon, not a feeling whose cause was hidden in the unconscious.

Bouton's reframing of extinction as inhibitory learning, developed through the 1990s and 2000s, had comparable consequences for treatment. It explained the stubborn relapse rate of exposure therapy not as therapeutic failure but as a property of the underlying memory system, and it generated concrete prescriptions — vary the context, repeat the exposure, consolidate over time — that are now standard. The reconsolidation research of Nader, Pitman, Brunet, and colleagues has continued this trajectory, raising the prospect of editing a memory at the moment it becomes labile.

Philosophically, these disorders press hardest on the relation between brain and agency. If fear runs through a subcortical circuit that fires before conscious appraisal, in what sense is the fearful person choosing their fear? The honest answer is that they are not, and this is exactly why pharmacological and exposure-based interventions are needed rather than mere willpower. At the same time, the efficacy of cognitive restructuring and the role of expectancy and perceived control show that top-down processes genuinely modulate the circuit. The nontrivial conclusion is that fear is neither freely chosen nor mechanistically fixed: it is a layered system in which conscious appraisal can, with effort and training, reshape automatic response — but only within the limits the circuitry imposes.

Bibliography Master

1. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text revision). Author.

2. LeDoux, J. E. (1996). The Emotional Brain: The Mysterious Underpinnings of Emotional Life. Simon & Schuster.

3. LeDoux, J. E. (2000). Emotion circuits in the brain. Annual Review of Neuroscience, 23, 155-184.

4. Davis, M., & Whalen, P. J. (2001). The amygdala: Vigilance and emotion. Molecular Psychiatry, 6(1), 13-34.

5. Phelps, E. A., Delgado, M. R., Nearing, K. I., & LeDoux, J. E. (2004). Extinction learning in humans: Role of the amygdala and vmPFC. Neuron, 43(6), 897-905.

6. Bouton, M. E. (2004). Context and behavioral processes in extinction. Learning & Memory, 11(5), 485-494.

7. Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99(1), 20-35.

8. Brewin, C. R., Gregory, J. D., Lipton, M., & Burgess, N. (2010). Intrusive images in psychological disorders: Characteristics, neural mechanisms, and treatment implications. Psychological Review, 117(1), 210-232.

9. Barlow, D. H. (2000). Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. American Psychologist, 55(11), 1247-1263.

10. Dugas, M. J., Gagnon, F., Ladouceur, R., & Freeston, M. H. (1998). Generalized anxiety disorder: A preliminary test of a conceptual model. Behaviour Research and Therapy, 36(2), 215-226.

11. Rauch, S. L., Jenike, M. A., Alpert, N. M., Baer, L., Breiter, H. C., Savage, C. R., & Fischman, A. J. (1994). Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Archives of General Psychiatry, 51(1), 62-70.

12. Baxter, L. R., Schwartz, J. M., Bergman, K. S., Szuba, M. P., Guze, B. H., Mazziotta, J. C., et al. (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry, 49(9), 681-684.

13. Brunet, A., Poundja, J., Tremblay, J., Bui, E., Thomas, E., Rotrling, P., et al. (2011). Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. Journal of Clinical Psychopharmacology, 31(4), 547-550.

14. Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., et al. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033.

15. Wolpe, J. (1958). Psychotherapy by Reciprocal Inhibition. Stanford University Press.

16. Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., et al. (1998). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. American Journal of Psychiatry, 155(2), 264-271.

17. Gleitman, H., Gross, J., & Reisberg, D. (2011). Psychology (8th ed.). W. W. Norton.

18. Myers, D. G., & DeWall, C. N. (2021). Psychology (13th ed.). Worth Publishers.